Foliglurax
Foliglurax
Foliglurax (pronounced: /foʊˈlɪgjʊræks/) is a novel pharmacological agent currently under investigation for its potential therapeutic applications in the treatment of Parkinson's disease.
Etymology
The term "Foliglurax" is derived from the Latin words 'folium' meaning leaf and 'glura' meaning glue, symbolizing the drug's potential to 'stick' to the targeted receptors in the brain and 'leaf' through the symptoms of Parkinson's disease.
Pharmacology
Foliglurax is a selective metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator. It works by enhancing the activity of the mGluR4 receptor, which is believed to have a neuroprotective effect in the dopaminergic system. This mechanism of action is thought to potentially alleviate the motor symptoms associated with Parkinson's disease.
Clinical Trials
Foliglurax has undergone Phase II clinical trials for the treatment of Parkinson's disease. The results have shown promise in reducing the motor complications and non-motor symptoms in patients with advanced Parkinson's disease.
Related Terms
See Also
External links
- Medical encyclopedia article on Foliglurax
- Wikipedia's article - Foliglurax
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski